2024年10月至2025年2月法国流感疫苗对社区中检测到的感染的有效性

Blanquart François, Vieillefond Vincent, Visseaux Benoit, Abou Chakra Claire Nour, Nunes Marta C, Jacques Alexandra, Haim-Boukobza Stephanie, Josset Laurence, Wehrle Valentin, Deleglise Guillaume, Duret Thomas, Rameix-Welti Marie Anne, Lina Bruno, Enouf Vincent, Bal Antonin

Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.

BPO-BIOEPINE-Biogroup, Levallois-Perret, France.

Euro Surveill. 2025 Feb;30(7). doi: 10.2807/1560-7917.ES.2025.30.7.2500074.

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

自2024年11月以来，流感在欧洲以高水平传播。利用一项基于2024年10月至2025年2月法国社区实验室数据的检测阴性研究，我们估计了针对PCR检测到的流感感染（44,420/15,052；阳性/阴性个体）的疫苗效力（VE）。对于所有年龄组，总体疫苗效力为42%（95%CI：37 - 46%），其中针对甲型流感为26%（95%CI：18 - 34%），针对乙型流感为75%（95%CI：66 - 82%）。在65岁及以上个体中，疫苗效力为22%（95%CI：13 - 30%），在0 - 64岁个体中为60%（95%CI：56 - 65%）。